|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Adar1 Capital Management LLC
✚
|
|
|---|---|
| CRD # | 299694 |
| SEC # | 801-130082 |
| CIK # | 0001940272 |
| AUM | $819.9 M (2025-03-31) |
| Employees | 9 (67% Investors, 0% Brokers) |
| Phone | 512-254-3790 |
| Address | 3503 Wild Cherry Drive Austin, TX 78738 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| CIK | Period |
|---|---|
| 0001940272 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Keros Therapeutics Inc | 71.9 | ||
| Protagonist Therapeutics Inc | 52.4 | ||
| Zai Lab Ltd | 29.7 | ||
| Abivax Sa | 23.5 | ||
| Roivant Sciences Ltd | 21.9 | ||
| Prothena Corp PLC | 20.5 | ||
| Cytokinetics Inc | 19.2 | ||
| CG Oncology Inc | 13.6 | ||
| Bridgebio Pharma Inc | 11.2 | ||
| Inhibikase Therapeutics Inc | 10.0 | ||
| Septerna Inc | 9.0 | ||
| Tekmira Pharmaceuticals Corp | 8.7 | ||
| 89bio Inc | 8.6 | ||
| Health Sciences Acquisitions Corp | 8.6 | ||
| Adventrx Pharmaceuticals Inc | 8.2 | ||
| Xenon Pharmaceuticals Inc | 8.1 | ||
| Bioage Labs Inc | 8.0 | ||
| Amylyx Pharmaceuticals Inc | 7.7 | ||
| Janux Therapeutics Inc | 7.6 | ||
| CytomX Therapeutics Inc | 7.0 | ||
| Taysha Gene Therapies Inc | 7.0 | ||
| RAPT Therapeutics Inc | 6.3 | ||
| ISIS Pharmaceuticals Inc | 5.9 | ||
| Teva Pharmaceutical Industries Ltd | 5.8 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | Adar1 SPV I LP | [2025-03-31] | 4.3 | 49.5 |
| HF | Adar1 Partners LP | [2024-03-28] | 4.3 | 676.0 |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 819.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 819.9 |
| By Discretionary | ||
| Discretionary | 5 | 819.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 819.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 319.4 | |
| United States Persons | 500.6 | |
| Total | 5 | 819.9 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| Daniel Schneeberger | 3 | ||
| Adar1 Capital Management LLC | 3 | ||
| Stephen Scipione | 1 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001940272] | |
| 3 | [0001940272] | |
| 4 | [0001940272] | |
| SC 13D | [0001940272] | |
| SC 13G | [0001940272] |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Fort Baker Capital Management LP
✚
|
CA | 0.8 |
|
Crow's Nest Holdings LP
✚
|
VA | 0.8 |
|
First Citizens Institutional Asset Management LLC
✚
|
NY | 0.8 |
|
Pinnbrook Capital Management LP
✚
|
NY | 0.8 |
|
Lykos Global Management LP
✚
|
CT | 0.8 |
|
Capeview Capital LLP
✚
|
0.8 | |
|
Affinity Asset Advisors LLC
✚
|
NY | 0.8 |
|
The Cypress Funds LLC
✚
|
CA | 0.8 |
|
Enhalus Capital LP
✚
|
NY | 0.8 |
|
BWCP LP
✚
|
TX | 0.8 |